[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Samsung Medical Center\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":603},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,112,0,25,[9,47,71,93,114,143,166,192,217,240,265,291,312,333,352,372,395,411,432,456,475,495,513,542,569],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100628866","phase-3-routine-use-of-potassium-competitive-acid-blocker-vs-guideline-directed-gastrointestinal-protection-strategy-in-acute-myocardial-infarction-100628866",false,"NCT07467213","Routine Use of Potassium Competitive Acid Blocker vs. Guideline-Directed Gastrointestinal Protection Strategy in Acute Myocardial Infarction","Routine Use of Potassium Competitive Acid Blocker Versus Guideline-Directed Gastrointestinal Protection Strategy in Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention on Dual Antiplatelet Therapy: A Randomized Trial","PCAB-AMI","Inclusion Criteria:\n\n* Patients aged 19 years or older.\n* Patients diagnosed with acute myocardial infarction (ST-segment elevation myocardial infarction \\[STEMI\\] or non-ST-segment elevation myocardial infarction \\[NSTEMI\\]).\n* Patients who underwent percutaneous coronary intervention (PCI) with drug-eluting stents (DES) or drug-coated balloons (DCB).\n* Patients (or their legal representatives) who understood the study risks and benefits and provided voluntary written informed consent.\n\nExclusion Criteria:\n\n* History of hypersensitivity (e.g., allergic reaction, anaphylactic shock) or contraindication to study drugs (potassium-competitive acid blocker \\[P-CAB\\] or proton pump inhibitor \\[PPI\\]).\n* Presence of active gastrointestinal bleeding.\n* Pregnant or breastfeeding women.\n* Non-cardiac life expectancy of less than 1 year or patients expected to have low compliance (as determined by the investigator's medical judgment).\n* Patients who refuse to participate or are unable to follow the requirements specified in the study protocol.","ALL","19 Years",{"count":21,"type":22},5000,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","This study aims to compare the clinical outcomes between routine use of potassium competitive acid blocker (P-CAB) and guideline-directed gastrointestinal (GI) protection strategy in patients with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI) and being treated with dual antiplatelet therapy (DAPT).",[28,29],"Acute Myocardial Infarction (AMI)","Gastrointestinal Bleeding",[31,32,33,34],"Percutaneous Coronary Intervention","Dual Antiplatelet Therapy","Potassium Competitive Acid Blocker","Zastaprazan","RECRUITING","2026-06-23",{"date":38,"type":39},"2026-06-26","ACTUAL",{"date":36,"type":39},{"date":42,"type":22},"2030-12-31",{"name":44,"class":45},"Samsung Medical Center","OTHER",1,{"id":48,"slug":49,"hasResults":12,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":12,"sex":18,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":4},"100642568","livalozet-versus-high-intensity-statin-in-older-patients-with-coronary-artery-disease-undergoing-percutaneous-coronary-intervention-100642568","NCT07626840","Livalozet Versus High-intensity Statin in Older Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention","Pitavastatin With Ezetimibe Combination Therapy Versus High-intensity Statin in Older Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention","SMARTDECISION2","Inclusion Criteria\n\n* Age 75 years or older\n* Patients diagnosed with stable coronary artery disease or acute coronary syndrome and requiring coronary artery intervention due to coronary artery stenosis\n* Patients with primary hypercholesterolemia and mixed dyslipidemia\n* Patients who understand the risks and benefits of treatment, as well as alternatives, and can voluntarily sign the informed consent form\n\nExclusion Criteria:\n\n* Patients with hypersensitivity or contraindications to statins or ezetimibe\n* Patients with active liver disease or persistently elevated AST or ALT levels exceeding three times the upper limit of normal\n* Patients with a history of organ transplantation (kidney, liver, etc.)\n* Pregnant or lactating women\n* Patients with a life expectancy of less than one year due to non-cardiac disease, or those deemed unable to participate in the study and follow-up (based on the medical judgment of the investigator at each site)","75 Years",{"count":21,"type":22},[58],"NA","Acute myocardial infarction is one of the leading causes of death in elderly patients, and the importance of lipid-lowering therapy as a secondary prevention strategy to reduce cardiovascular events is emphasized. The European Society of Cardiology (ESC) and American Heart Association (AHA) guidelines recommend lowering low-density lipoprotein-cholesterol (LDL-C) below 55 mg\u002FdL or by at least 50% from baseline as a treatment goal and recommend high-intensity statin therapy (Atorvastatin 40-80 mg, Rosuvastatin 20 mg). Statins have been shown to reduce cardiovascular risk in elderly patients as well. However, these patients exhibit a higher rate of statin intolerance due to side effects associated with high-intensity statins, such as myalgia, hepatotoxicity, cognitive decline, and increased risk of diabetes. Consequently, dose reduction or discontinuation is required more frequently compared to younger patients. Therefore, establishing an appropriate lipid-lowering strategy for elderly patients is necessary, considering not only efficacy but also drug tolerability. Consequently, in elderly patients, reducing the statin intensity from the outset and considering combination therapy with drugs having different mechanisms of action, such as ezetimibe, may be warranted. Pitavastatin is classified as a moderate-intensity statin. Previous studies have confirmed that Pitavastatin demonstrates non-inferior efficacy compared to Rosuvastatin and Atorvastatin. Several observational studies report that Pitavastatin has fewer drug interactions than other statins and lower rates of diabetes onset and elevated liver enzymes. Therefore, Pitavastatin may be an appropriate choice for moderate-intensity statin therapy in elderly patients. Thus, this study aims to evaluate whether combination therapy with Pitavastatin and Ezetimibe (Livalozet 4\u002F10mg) after coronary intervention in patients aged 75 years or older with coronary artery disease is non-inferior to high-intensity statin therapy (Atorvastatin 40-80 mg or Rosuvastatin 20 mg). If this study demonstrates that moderate-intensity statin therapy combined with ezetimibe is non-inferior to high-intensity statin therapy while also having fewer adverse effects, it could provide evidence for an effective and safe cholesterol treatment option for elderly patients.",[61],"Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)","NOT_YET_RECRUITING","2026-06-08",{"date":65,"type":39},"2026-06-10",{"date":67,"type":22},"2026-06-01",{"date":69,"type":22},"2031-12-31",{"name":44,"class":45},{"id":72,"slug":73,"hasResults":12,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":23,"phases":81,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":46},"100643149","oxiris-in-septic-aki-100643149","NCT07641660","Oxiris in Septic AKI","Impact of Oxiris on Endothelial Cell Dysfunction and Renal Recovery in Patients With Septic Acute Kidney Injury","Inclusion Criteria:\n\n* Adult patients with AKI, aged ≥ 19 years old\n* Relevant disease states: sepsis-associated AKI\n\nExclusion Criteria:\n\n* Age \\> 85 years old\n* Uncontrolled malignancy\n* End-stage kidney disease\n* End-stage hepatic failure requiring MARS or liver transplantation\n* End-stage heart failure requiring extracorporeal membrane oxygenation (ECMO), left ventricular assist device (LVAD), intra-aortic balloon pump (IABP), or heart transplantation","84 Years",{"count":80,"type":22},32,[58],"Sepsis is a leading cause of acute kidney injury (AKI) in critically ill patients, with sepsis-associated AKI accounting for approximately 50% of all AKI cases in the intensive care unit. The pathophysiology of septic AKI involves a complex interplay of inflammation, endothelial dysfunction, and microvascular injury, leading to impaired renal perfusion and tubular damage. Despite advances in critical care, septic AKI remains associated with high mortality rates and significant risk of progression to chronic kidney disease.\n\nContinuous renal replacement therapy (CRRT) is the standard extracorporeal treatment for AKI in hemodynamically unstable patients. The Oxiris hemofilter (Baxter\u002FVantive) is a specialized AN69-based membrane with enhanced adsorptive capacity for cytokines and endotoxins due to a polyethyleneimine surface treatment and heparin grafting. While Oxiris has demonstrated the ability to reduce circulating inflammatory mediators in septic patients, its impact on endothelial cell dysfunction and subsequent renal recovery has not been systematically evaluated.\n\nThis is a single-center, prospective, open-label, exploratory randomized controlled trial comparing CRRT using the Oxiris filter versus CRRT using a standard filter in patients with sepsis-associated AKI at Samsung Medical Center, Seoul, Korea. A total of 30 patients (15 per group) will be enrolled and allocated using stratified randomization based on SOFA score, baseline renal function, and presence of septic shock.\n\nEligible participants are adult patients (aged 19 years or older) diagnosed with sepsis according to Sepsis-3 criteria who develop AKI (KDIGO stage 2 or higher) requiring CRRT initiation. Key exclusion criteria include end-stage kidney disease, expected survival of less than 24 hours, prior CRRT within 72 hours, and contraindications to heparin-based anticoagulation. CRRT will be maintained for a minimum of 72 hours, with Oxiris filters replaced every 24 hours per manufacturer guidelines.\n\nThe primary endpoints are changes in endothelial cell function assessed using induced pluripotent stem cell-derived endothelial cells (iPSC-ECs) treated with patient plasma collected at three time points: CRRT initiation (baseline), day 3, and CRRT discontinuation. Endothelial function will be evaluated by tube formation assay (total tube length, branch points, mesh area) and reactive oxygen species (ROS) production. This iPSC-EC-based model provides a reproducible and standardized platform to directly assess the biological effects of Oxiris on vascular endothelial integrity under conditions mimicking the pathophysiological environment of septic AKI.\n\nSecondary endpoints include 90-day all-cause mortality, renal recovery (defined as dialysis independence at 90 days), changes in hemodynamic parameters (vasopressor requirements, mean arterial pressure), CRRT duration, and serial measurements of blood and urine biomarkers including NGAL, KIM-1, MCP-1, RANTES, and TGF-beta. These biomarkers reflect inflammatory burden, endothelial dysfunction, and renal tubular injury, providing a comprehensive assessment of the therapeutic effects of Oxiris beyond standard cytokine clearance.\n\nAs this is an exploratory study, all p-values will be interpreted descriptively and results will be used to generate hypotheses and inform the design of future confirmatory trials. The study aims to provide mechanistic insights into whether enhanced cytokine and endotoxin removal by Oxiris translates into measurable improvements in endothelial function and clinical renal outcomes.",[84],"Sepsis-associated AKI","2026-06-07",{"date":87,"type":39},"2026-06-11",{"date":89,"type":22},"2026-06-16",{"date":91,"type":22},"2029-03-09",{"name":44,"class":45},{"id":94,"slug":95,"hasResults":12,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":100,"enrollmentInfo":101,"targetDuration":4,"studyType":23,"phases":103,"briefSummary":104,"conditions":105,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":110,"completionDateStruct":111,"leadSponsor":113,"locationsCount":4},"100643743","effect-of-individualized-positive-end-expiratory-pressure-peep-in-patients-who-have-an-intrinsic-peep-during-one-lung-ventilation-100643743","NCT07638176","Effect of Individualized Positive End-expiratory Pressure (PEEP) in Patients Who Have an Intrinsic PEEP During One-lung Ventilation","Effects of Individualized Positive End-expiratory Pressure (PEEP) on Intrinsic PEEP and Stroke Volume During One-lung Ventilation: a Single-center, Randomized Crossover Study","Inclusion Criteria:\n\n* American Society of Anesthesiologists Physical Status I - III\n* The Eastern Cooperative Oncology Group Performance Status Grade 0 - 2\n* Lung resection surgery requiring one-lung ventilation for over 60 minutes\n* Indication of double-lumen endobronchial tube (female 35 Fr, male 37 Fr)\n* Patient who is diagnosed with intrinsic PEEP during one-lung ventilation\n\nExclusion Criteria:\n\n* Large bullae\n* Emergency surgery\n* Mechanical ventilation before surgery\n* Hemodynamic instability before surgery\n* Surgery requiring cardiopulmonary bypass\n* Pregnancy, breastfeeding patient\n* Patient's refusal to participate\n* No intrinsic PEEP during one-lung ventilation","100 Years",{"count":102,"type":22},48,[58],"This study investigates the effects of three extrinsic PEEP settings-5 cmH2O, 0 cmH2O, and an individualized PEEP (70% of the measured intrinsic PEEP)-on intrinsic PEEP and hemodynamic stability in patients with intrinsic PEEP undergoing lung resection surgery, using a randomized, crossover design.",[106,107],"Pulmonary Disease (COPD), Chronic Obstructive","Lung Resection Surgery","2026-06-04",{"date":65,"type":39},{"date":67,"type":22},{"date":112,"type":22},"2027-05-31",{"name":44,"class":45},{"id":115,"slug":116,"hasResults":12,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":12,"sex":18,"minAge":121,"maxAge":122,"enrollmentInfo":123,"targetDuration":4,"studyType":125,"phases":4,"briefSummary":126,"conditions":127,"keywords":129,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":142},"100641231","a-korean-point-prevalence-study-of-acute-rehabilitation-for-kids-in-the-picu-park-picu-100641231","NCT07629297","A Korean Point Prevalence Study of Acute Rehabilitation for Kids in the PICU (PARK-PICU)","Prevalence of Acute Rehabilitation for Kids in the Pediatric Intensive Care Unit","Inclusion Criteria:\n\n* Children and adolescents aged 18 years or younger who have been admitted to the pediatric intensive care unit (PICU) for at least 72 hours as of 9:00 AM on the predefined study date at participating hospitals.\n\nExclusion Criteria:\n\n* No exclusion criteria. All eligible patients meeting the inclusion criteria will be included to comprehensively assess the real-world prevalence of acute rehabilitation practices and associated barriers in pediatric intensive care units.","0 Days","18 Years",{"count":124,"type":22},396,"OBSERVATIONAL","This study investigates the prevalence of acute rehabilitation practices among children in pediatric intensive care units (PICUs).",[128],"Pediatric Intensive Care Units",[128,130,131,132,133,134],"Acute Rehabilitation","Rehabilitation Prevalence","Child","Critical Illness","Intensive Care Unit Acquired Weakness",{"date":136,"type":39},"2026-06-05",{"date":138,"type":22},"2026-05-28",{"date":140,"type":22},"2027-12-31",{"name":44,"class":45},13,{"id":144,"slug":145,"hasResults":12,"nctId":146,"briefTitle":147,"officialTitle":147,"acronym":148,"eligibilityCriteria":149,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":150,"targetDuration":4,"studyType":125,"phases":4,"briefSummary":152,"conditions":153,"keywords":156,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":46},"100640652","efficacy-of-early-rhythm-control-in-af-with-tr-patients-100640652","NCT07607093","Efficacy of Early Rhythm Control in AF With TR Patients","TRAF","Inclusion Criteria:\n\n* Patients with concomitant atrial fibrillation and tricuspid regurgitation.\n\nExclusion Criteria:\n\n* Patients with a history of valvular surgery\n* Patients with congenital heart disease\n* Patients with primary pulmonary hypertension\n* Patients with CIED implantation prior to the diagnosis of tricuspid regurgitation\n* Patients diagnosed with TR only after the initiation of rhythm control therapy for AF",{"count":151,"type":22},5800,"Atrial fibrillation is frequently accompanied by tricuspid regurgitation and may contribute to right atrial and tricuspid annular remodeling, leading to progression of tricuspid regurgitation and adverse clinical outcomes. However, whether early rhythm control improves prognosis in patients with atrial fibrillation and tricuspid regurgitation remains unclear. This study will compare early rhythm control with usual care in these patients, using a composite outcome of cardiac death, heart failure admission, stroke, and tricuspid valve surgery.",[154,155],"Atrial Fibrillation (AF)","Tricuspid Regurgitation (TR)",[157],"early rhythm control","2026-05-27",{"date":160,"type":39},"2026-05-29",{"date":162,"type":39},"2026-02-18",{"date":164,"type":22},"2027-02-28",{"name":44,"class":45},{"id":167,"slug":168,"hasResults":12,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":4,"eligibilityCriteria":172,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":23,"phases":175,"briefSummary":176,"conditions":177,"keywords":182,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":46},"100637792","pulsar-combined-with-immunotherapy-for-unresectable-locally-advanced-gastric-cancer-100637792","NCT07607119","PULSAR Combined With Immunotherapy for Unresectable Locally Advanced Gastric Cancer","A Prospective Phase II Study of Systemic Therapy With Immunotherapy Combined With Personalized Ultrafractionated Stereotactic Adaptive Radiation Therapy (PULSAR) in Unresectable Locally Advanced Gastric Cancer","Inclusion Criteria:\n\nAge 19 or more years. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2. Histologically confirmed gastric adenocarcinoma. Tumor biomarker status: HER-2 negative, EBV negative, and Microsatellite Stable (MSS).\n\nUnresectable, locally advanced extent at initial staging (Para-aortic lymph node \\[PALN\\] and Supraclavicular lymph node \\[SCN\\] metastases are allowed).\n\nHas completed 3 or more cycles of first-line systemic therapy combined with immunotherapy without evidence of disease progression.\n\nPresence of at least one evaluable lesion according to RECIST v1.1 that is deemed safely irradiable by the investigator.\n\nVoluntary written informed consent provided by the subject.\n\nExclusion Criteria:\n\nPregnant or lactating women. Presence of brain metastases or leptomeningeal involvement. Prior history of radiation therapy to the intended target site. Severe uncontrolled comorbidities that, in the investigator's opinion, limit study participation or treatment compliance (e.g., uncontrolled infection, heart failure, arrhythmia, psychiatric illness).\n\nInability or unwillingness to comply with the study protocol procedures. Any condition deemed inappropriate for study participation by the principal investigator or attending physician.",{"count":174,"type":22},53,[58],"The purpose of this prospective, single-center, phase II study is to evaluate the clinical efficacy and safety of combining first-line systemic therapy plus immunotherapy with personalized ultrafractionated stereotactic adaptive radiation therapy (PULSAR) in patients with unresectable locally advanced gastric cancer.",[178,179,180,181],"Gastric Adenocarcinoma","Stomach Neoplasms","Locally Advanced Gastric Cancer","Unresectable Gastric Cancer",[183,184],"HER2-negative Stomach Cancer","Microsatellite Stable Gastric Cancer","2026-05-24",{"date":138,"type":39},{"date":188,"type":39},"2026-05-15",{"date":190,"type":22},"2030-04-30",{"name":44,"class":45},{"id":193,"slug":194,"hasResults":12,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":4,"eligibilityCriteria":198,"healthyVolunteers":12,"sex":18,"minAge":122,"maxAge":4,"enrollmentInfo":199,"targetDuration":4,"studyType":125,"phases":4,"briefSummary":201,"conditions":202,"keywords":206,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":46},"100640243","dumping-syndrome-after-esophagectomy-100640243","NCT07605481","Dumping Syndrome After Esophagectomy","Prospective Observational Study on the Utility of Continuous Glucose Monitoring for the Diagnosis of Dumping Syndrome After Esophagectomy","Inclusion Criteria:\n\n-1. aged 18 or older. 2. people who underwent esophagectomy and gastric tube reconstruction for esophageal cancer.\n\n3\\. Sigstad score of 7 or higher.\n\nExclusion Criteria:\n\n* 1\\. Diabetes with autonomic neuropathy. 2. Inability to complete the diagnostic procedure (e.g., cognitive decline). 3. Refusal to participate.",{"count":200,"type":22},30,"Background:\n\nDumping syndrome is a common complication for patients who have undergone surgery for esophageal cancer. It occurs when food moves too quickly from the stomach (or the reconstructed gastric tube) into the small intestine. This rapid movement causes various symptoms such as bloating, abdominal pain, dizziness, rapid heartbeat, and sweating. Sometimes, it leads to \"late dumping,\" where blood sugar levels drop significantly, causing tremors, cold sweats, and fatigue. Currently, there is no standardized tool to easily diagnose this condition after esophagectomy.\n\nPurpose of the Study:\n\nThe objective of this study is to evaluate the effectiveness of Continuous Glucose Monitoring (CGM) in diagnosing dumping syndrome. CGM is a small, wearable sensor that tracks glucose levels in real-time. The investigators aim to determine whether CGM can serve as a valuable tool for the early detection of dumping syndrome in patients who have undergone esophagectomy.",[203,204,205],"Esophagectomy","Dumping Syndrome","Continous Glucose Measurement",[207,208],"esophagectomy","dumping syndrome","2026-05-21",{"date":211,"type":39},"2026-05-26",{"date":213,"type":22},"2026-06-15",{"date":215,"type":22},"2028-12-31",{"name":44,"class":45},{"id":218,"slug":219,"hasResults":12,"nctId":220,"briefTitle":221,"officialTitle":221,"acronym":222,"eligibilityCriteria":223,"healthyVolunteers":12,"sex":18,"minAge":122,"maxAge":4,"enrollmentInfo":224,"targetDuration":226,"studyType":125,"phases":4,"briefSummary":227,"conditions":228,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":46},"100635933","imaging-based-prediction-of-eligibility-for-chemoimmunotherapy-in-resectable-nsclc-iprecise-100635933","NCT07559123","Imaging-based PRediction of Eligibility for ChemoImmunotherapy in reSEctable NSCLC, iPRECISE","iPRECISE","Inclusion Criteria:\n\n* Age: 18 years or older.\n* Diagnosis: Histologically or cytologically confirmed non-small cell lung cancer (NSCLC).\n* Staging: Resectable NSCLC of stage IIIA or lower.\n* Treatment Plan: Planned to receive neoadjuvant chemoimmunotherapy before surgery according to standard clinical practice.\n* Performance Status: Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Informed Consent: Able and willing to provide written informed consent after receiving a detailed explanation of the study.\n\nExclusion Criteria:\n\n* No Measurable Lesion: Participants must have at least one measurable lesion (\\>= 10 mm on spiral\u002Fmultidetector computed tomography).\n* Prior Malignancy: History of another malignancy within 5 years before enrollment (excluding adequately treated basal cell skin carcinoma or cervical carcinoma in situ).\n* Neurological\u002FPsychiatric Conditions: History of clinically significant uncontrolled seizures, CNS disease, or psychiatric disorders that may interfere with study participation or consent.\n* Contrast Allergy: History of severe allergic reaction to iodinated CT contrast media.\n* Renal Impairment: Acute renal failure or moderate to severe renal impairment (CrCl \\\u003C 45 mL\u002Fmin\u002F1.73 m² or serum creatinine \\> 1.5x upper limit of normal).\n* Recent Surgery: Major surgery within 4 weeks of enrollment or incomplete recovery from major surgery.\n* Pregnancy\u002FNursing: Currently pregnant or breastfeeding; women of childbearing potential without a negative baseline pregnancy test.\n* Contraception: Men or women of childbearing potential unwilling to use appropriate contraception during the study.",{"count":225,"type":22},150,"3 Years","This study is for adults with resectable non-small cell lung cancer who are scheduled to receive neoadjuvant chemoimmunotherapy before surgery.\n\nNeoadjuvant chemoimmunotherapy can help shrink lung cancer before surgery and may improve treatment outcomes. However, not all patients benefit from this treatment in the same way, and it can sometimes cause side effects, such as immune-related pneumonitis. At present, it is still difficult to predict before or during treatment which patients will have a strong response.\n\nThe purpose of this study is to find imaging features on chest computed tomography scans that may help predict how well a patient's cancer responds to neoadjuvant chemoimmunotherapy. The study will compare computed tomography findings before treatment and before surgery with pathologic findings from surgery, including pathologic complete response and major pathologic response. The study will also evaluate whether computed tomography-based imaging features are associated with treatment-related side effects and long-term outcomes such as disease progression and survival.\n\nThis is an observational study. The investigators will not assign participants to a specific cancer treatment. Participants will receive neoadjuvant chemoimmunotherapy and surgery according to standard clinical practice. Chest computed tomography scans will be obtained before treatment and before surgery as part of the study protocol. These computed tomography images will also be reconstructed using a high-resolution deep learning-based computed tomography reconstruction technique to explore whether this approach can improve the development of imaging biomarkers.\n\nThe results of this study may help develop a noninvasive imaging-based model to identify patients who are more likely to benefit from neoadjuvant chemoimmunotherapy and to better guide treatment planning for resectable non-small cell lung cancer.",[229,230,231],"NSCLC","Neoadjuvant Chemoimmunotherapy","CT","2026-05-05",{"date":234,"type":39},"2026-05-08",{"date":236,"type":39},"2026-02-01",{"date":238,"type":22},"2028-12",{"name":44,"class":45},{"id":241,"slug":242,"hasResults":12,"nctId":243,"briefTitle":244,"officialTitle":244,"acronym":245,"eligibilityCriteria":246,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":247,"targetDuration":4,"studyType":23,"phases":249,"briefSummary":250,"conditions":251,"keywords":253,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":259,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":46},"100636578","early-detection-of-concealed-cardiac-amyloidosis-using-ai-ecg-and-ct-derived-extracellular-volume-in-patients-with-atrial-fibrillation-100636578","NCT07567508","Early Detection of Concealed Cardiac Amyloidosis Using AI-ECG and CT-Derived Extracellular Volume in Patients With Atrial Fibrillation","SEARCH-AF","Inclusion Criteria:\n\n* Adults aged 19 or older who have provided voluntary written informed consent.\n* Patients with a history of AF (paroxysmal or persistent) and one or more red-flag symptoms\u002Fsigns.\n* Patients who can undergo at least one of the following: AI-ECG analysis or CT-ECV analysis.\n\nExclusion Criteria:\n\n* Patients previously diagnosed with cardiac amyloidosis (AL or ATTR).\n* Patients with severe heart failure (NYHA class IV) or terminal illness with a life expectancy of less than 1 year.\n* Patients deemed inappropriate for participation by the investigator.",{"count":248,"type":22},500,[58],"This study investigates the clinical efficacy of a non-invasive screening protocol using AI-ECG and CT-ECV analysis for cardiac amyloidosis. The study targets on atrial fibrillation(AF) patients with \"red-flag\" indicators.\n\nParticipants are randomized 1:1 into either an early screening or usual care group.\n\n* Early screening group : AI- ECG and\u002For CT-ECV analysis + AF treatment\n* Usual care group : AF treatment Both groups followed for 2 years to compare CA detection rates and clinical outcomes.",[154,252],"Cardiac Amyloidosis",[254,255,256,257],"AI-ECG","Amyloidosis","Cardiac amyloidosis","Atrial Fibrillation","2026-04-28",{"date":232,"type":39},{"date":261,"type":22},"2026-05",{"date":263,"type":22},"2029-12-31",{"name":44,"class":45},{"id":266,"slug":267,"hasResults":12,"nctId":268,"briefTitle":269,"officialTitle":270,"acronym":271,"eligibilityCriteria":272,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":273,"targetDuration":4,"studyType":23,"phases":275,"briefSummary":276,"conditions":277,"keywords":280,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":285,"startDateStruct":287,"completionDateStruct":289,"leadSponsor":290,"locationsCount":46},"100636243","impact-of-optimized-pacing-strategies-on-clinical-and-hemodynamic-outcomes-in-heart-failure-patients-with-pacemaker-100636243","NCT07563153","Impact of Optimized Pacing Strategies on Clinical and Hemodynamic Outcomes in Heart Failure Patients With Pacemaker","Clinical and Hemodynamic Outcomes of OPTimized PACing StratEgies in Heart Failure Patients With Pacing Indications: Randomized-Controlled Trial (OPTPACE-HF)","OPTPACE-HF","Inclusion Criteria:\n\n* Patients with symptomatic bradycardia who meet the indication for permanent pacemaker implantation and fulfill one of the following conditions:\n\n  1. Sick sinus syndrome with or without impaired atrioventricular conduction\n  2. Persistent or permanent atrial fibrillation with slow ventricular response\n  3. Chronotropic incompetence\n* Patients diagnosed with heart failure with left ventricular ejection fraction ≥ 50% on transthoracic echocardiography with at least one of the following:\n* H2FPEF score ≥ 6 or HFA-PEFF score ≥ 5\n* N-terminal pro-B-type natriuretic peptide ≥ 300 pg\u002FmL (sinus rhythm) or ≥ 600 pg\u002FmL (atrial fibrillation)\n* Prior hospitalization for heart failure or documented use of loop diuretics for heart failure symptoms\n\nExclusion Criteria:\n\n* Patients expected to have a ventricular pacing burden ≥ 20% without sufficient capture of cardiac physiologic pacing, which includes biventricular pacing, His bundle pacing, and left bundle branch area pacing.\n\n(Sufficient cardiac physiologic pacing is defined as a paced QRS duration ≤ 140 ms.)\n\n* Patients not expected to achieve sufficient pacing dependency, defined as:\n\n  1. In sinus rhythm: baseline atrial rate \\> 60 bpm on Holter monitoring or inpatient ECG monitoring\n  2. In atrial fibrillation\u002Fflutter: baseline ventricular rate \\> 60 bpm on Holter monitoring or inpatient ECG monitoring\n* Patients with contraindications to permanent pacemaker implantation\n* Patients with moderate or greater valvular stenosis or regurgitation.\n* Patients with dyspnea not attributable to heart failure, due to uncontrolled comorbid conditions\n* Pregnant or breastfeeding women.\n* Patients who have refused active treatment.",{"count":274,"type":22},106,[58],"This study aims to evaluate the clinical impact of an optimized pacing strategy in patients with heart failure.\n\n* Intervention: Adjustment of the pacemaker lower rate limit to an individualized, hemodynamically optimized heart rate.\n* Primary Endpoint: Heart failure symptoms, assessed by the Kansas City Cardiomyopathy Questionnaire score.\n* Hypothesis: In patients with heart failure requiring permanent pacing, an optimized pacing strategy will lead to a significant improvement in heart failure symptoms (Kansas City Cardiomyopathy Questionnaire score) at 12 months compared with the conventional pacing strategy.",[278,279],"Heart Failure","Bradycardia",[281,282,283,284],"Heart failure","bradycardia","CIED","lower rate",{"date":286,"type":39},"2026-05-01",{"date":288,"type":39},"2025-12-18",{"date":215,"type":22},{"name":44,"class":45},{"id":292,"slug":293,"hasResults":12,"nctId":294,"briefTitle":295,"officialTitle":295,"acronym":4,"eligibilityCriteria":296,"healthyVolunteers":12,"sex":18,"minAge":297,"maxAge":4,"enrollmentInfo":298,"targetDuration":4,"studyType":23,"phases":300,"briefSummary":302,"conditions":303,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":306,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":311,"locationsCount":4},"100616075","phase-2-t-cell-inflamed-gene-expression-profiling-score-guided-anti-pd-1-therapy-tislelizumab-monotherapy-for-refractory-solid-cancer-patients-unexposed-to-immunotherapy-100616075","NCT07300891","T Cell Inflamed Gene Expression Profiling Score-guided Anti PD-1 Therapy (Tislelizumab Monotherapy) for Refractory Solid Cancer Patients Unexposed to Immunotherapy","Inclusion Criteria:\n\n1. Patients aged ≥ 20 years at the time of informed consent.\n2. Patients with histologically- or cytologically confirmed advanced or metastatic solid tumor who are no longer benefiting from standard anti-cancer treatment or for whom, in the opinion of site physicians, no such treatment is available or indicated according to local or international guidelines.\n3. Centrally confirmed T cell inflamed GEP score ≥ 0.857 assessed by RNA sequencing. For baseline T cell inflamed GEP, an archived tissue sample collected within 2 years from the first dose of study drug must be provided. T cell inflamed gene expression profiling will be assessed at a central laboratory. Patients who have at least 1 target lesion per the Response Evaluation Criteria in Solid Tumors (RECIST) Guideline Ver. 1.1 as confirmed by imaging within 28 days before first dose of study drug.\n4. ECOG Performance Status Score 0 or 1.\n5. Patients with a life expectancy of at least 3 months.\n6. Patients with adequate hematological and biological function as indicated by the following screening laboratory values:\n\n   * Absolute neutrophil count (ANC) ≥ 1.5×109\u002FL\n   * Platelets ≥ 75×109\u002FL\n   * Hemoglobin ≥ 9g\u002FdL or ≥ 5.6 mmol\u002FL (Note: Criteria must be met without a transfusion within 14 days of obtaining the sample)\n   * Calculated creatinine clearance ≤ 1.5×upper limit of normal (ULN), or estimated GFR ≥ 60 mL\u002Fmin by Cockcroft-Gault formula\n   * Serum total bilirubin ≤ 1.5×ULN (total bilirubin must be \\\u003C 3×ULN for patients with Gilbert's syndrome)\n   * Aspartate aminotransferase (AST) and ALT ≤ 3×ULN OR ≤ 5×ULN for patients with liver metastases\n\nExclusion Criteria:\n\n1. Patients aged ≥ 20 years at the time of informed consent.\n2. Patients with histologically- or cytologically confirmed advanced or metastatic solid tumor who are no longer benefiting from standard anti-cancer treatment or for whom, in the opinion of site physicians, no such treatment is available or indicated according to local or international guidelines.\n3. Centrally confirmed T cell inflamed GEP score ≥ 0.857 assessed by RNA sequencing. For baseline T cell inflamed GEP, an archived tissue sample collected within 2 years from the first dose of study drug must be provided. T cell inflamed gene expression profiling will be assessed at a central laboratory. Patients who have at least 1 target lesion per the Response Evaluation Criteria in Solid Tumors (RECIST) Guideline Ver. 1.1 as confirmed by imaging within 28 days before first dose of study drug.\n4. ECOG Performance Status Score 0 or 1.\n5. Patients with a life expectancy of at least 3 months.\n6. Patients with adequate hematological and biological function as indicated by the following screening laboratory values:\n\n   * Absolute neutrophil count (ANC) ≥ 1.5×109\u002FL\n   * Platelets ≥ 75×109\u002FL\n   * Hemoglobin ≥ 9g\u002FdL or ≥ 5.6 mmol\u002FL (Note: Criteria must be met without a transfusion within 14 days of obtaining the sample)\n   * Calculated creatinine clearance ≤ 1.5×upper limit of normal (ULN), or estimated GFR ≥ 60 mL\u002Fmin by Cockcroft-Gault formula\n   * Serum total bilirubin ≤ 1.5×ULN (total bilirubin must be \\\u003C 3×ULN for patients with Gilbert's syndrome)\n   * Aspartate aminotransferase (AST) and ALT ≤ 3×ULN OR ≤ 5×ULN for patients with liver metastases\n\nKey exclusion criteria Patients who meet any of the following criteria at the time of assessment will be excluded.\n\n1. Patients with solid tumors from multiple primary origin (with the exception of completely resected basal cell carcinoma, stage I squamous cell carcinoma, carcinoma in situ, intramucosal carcinoma, or superficial bladder cancer, or any other cancer that has not recurred for at least 3 years).\n2. Patients with residual adverse effects of prior therapy or effects of surgery that would affect the safety evaluation of the investigational product in the opinion of the investigator or sub-investigator.\n3. Patients are expected to require any other form of systemic or localized antineoplastic therapy while on trial (including radiation therapy, and\u002For surgical resection).\n4. Patients who have previously received treatment with PD-1\u002FPD-L1 inhibitor or CTLA-4 inhibitor e.g. pembrolizumab, nivolumab, cemiplimab, atezolizumab, avelumab, durvalumab, tislelizumab, dostarlimab, spartalizumab tremelimumab or ipilimumab\n5. Active leptomeningeal disease or uncontrolled brain metastasis. Patients with equivocal findings or with confirmed brain metastases are eligible for enrollment provided that they are asymptomatic and radiologically stable without the need for corticosteroid treatment for ≥ 4 weeks before first dose of study drug.\n6. Patients have a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study in terms of efficacy and safety, interfere with the subject's participation for the full duration of the trial, or are not in the best interest of the subject to participate, in the opinion of the treating investigator.\n7. Women who are pregnant or breastfeeding, or possibly pregnant.\n8. Patients who have received any other unapproved drug (e.g., investigational use of drugs, unapproved combined formulations, or unapproved dosage forms) within 28 days before first dose of study drug.","20 Years",{"count":299,"type":22},72,[301],"PHASE2","This is a Phase 2, single-arm, multicenter study, evaluating the anti-tumor efficacy of tumor-infiltrating lymphocyte (TIL) directed tislelizumab monotherapy (also known as BGB-A317) for refractory solid tumors in approximately 72 patients with centrally confirmed T cell inflamed GEP score ≥ 0.857, who have not been previously exposed to immunotherapy.\n\nAll patients must provide a tumor specimen for T cell inflamed GEP assessment. Archived tissue slide collected within 2 years from the first dose of study drug must be provided.\n\nThis study will include a Screening Period, a Treatment Period, and a Follow-Up Period. All patients will complete up to 28 days of screening. During the Treatment Period, patients will receive tislelizumab 200 mg fixed dose once every 3 weeks by intravenous (IV) administration until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.\n\nAfter treatment discontinuation, patients will be follow-up for disease progression and survival status until death, withdrawal of consent, or study closure, whichever occurs first.\n\nThe end of study will be the timepoint when the final data for the study were collected. Additionally, the Investigator Sponsor has the right to terminate this study at any time.",[304],"Refractory Solid Cancer Patients Unexposed to Immunotherapy","2026-04-26",{"date":258,"type":39},{"date":308,"type":22},"2026-08",{"date":310,"type":22},"2028-01-31",{"name":44,"class":45},{"id":313,"slug":314,"hasResults":12,"nctId":315,"briefTitle":316,"officialTitle":317,"acronym":4,"eligibilityCriteria":318,"healthyVolunteers":319,"sex":18,"minAge":320,"maxAge":55,"enrollmentInfo":321,"targetDuration":4,"studyType":23,"phases":323,"briefSummary":324,"conditions":325,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":327,"startDateStruct":328,"completionDateStruct":330,"leadSponsor":332,"locationsCount":46},"100479859","phase-2-osimertinib-to-suppress-the-progression-of-remaining-ggn-for-egfr-mutation-positive-stage-ib-iiia-lung-adenocarcinoma-100479859","NCT05528458","Osimertinib to Suppress the Progression of Remaining GGN for EGFR Mutation-positive Stage IB-IIIA Lung Adenocarcinoma","A Phase II Study of Osimertinib to Suppress the Progression of Remaining Ground-glass Opacity Nodule (GGN) for Actionable EGFR Mutation-positive Stage IB-IIIA Lung Adenocarcinoma","Inclusion Criteria:\n\n1. Provision of informed consent prior to any study specific procedures\n2. Adult male or female patients, aged from 30 to 75 years\n3. Pathologic proven lung adenocarcinoma with additional persistent GGNs in at least one other lobe: GGN is defined as a ground glass-opacity with well-defined margin, mean density above -500 HU and greater than 7.5 mm in its maximum diameter\n4. The resected lung adenocarcinoma should have actionable EGFR mutation, which is limited to L858R or exon 19 deletion.\n5. WHO performance status 0-1 with no deterioration over the previous 2 weeks and a minimum life expectancy of 12 weeks\n6. Complete surgical resection of the primary NSCLC is mandatory.\n7. Uneventful recovery from curative-intent lung cancer surgery\n\nFor assignment in the control arm, subjects should be classified post-operatively as Stage IA on the basis of pathologic criteria (the 8th edition of TNM staging system for lung cancer).\n\nFor assignment in the treatment arm, subjects should fulfil the following criteria in addition to the above criteria.\n\n* Patients must be classified post-operatively as Stage IB, II or IIIA on the basis of pathologic cirteria (the 8th edition of TNM staging system for lung cancer)\n* Female subjects should be using highly effective contraceptive measures, and must have a negative pregnancy test and not be breast-feeding prior to start of dosing if of child-bearing potential or must have evidence of non-child-bearing potential by fulfilling one of the following criteria at screening:\n\n  * Post-menopausal defined as aged more than 50 years and amenorrheic for at least 12 months following cessation of all exogenous hormonal treatments\n  * Women under 50 years old would be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and with LH and FSH levels in the post-menopausal range for the institution\n  * Documentation of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation\n\nFurther information in Appendix E (Definition of Women of Childbearing Potential and Acceptable Contraceptive Methods)\n\n\\- Male subjects should be willing to use barrier contraception during the study and for 4 months after last dose of osimertinib\n\nExclusion Criteria:\n\n1. Regression of synchronous GGN after adjuvant chemotherapy prior to osimertinib\n2. Past history of postoperative ALI\u002FARDS or pneumonia during recovery period\n3. Currently receiving (or unable to stop use prior to receiving the first dose of study treatment) medications or herbal supplements known to be strong inducers of CYP3A4 (at least 3 week prior) (Appendix C). All patients must try to avoid concomitant use of any medications, herbal supplements and\u002For ingestion of foods with known inducer effects on CYP3A4.\n4. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses, which in the investigator's opinion makes it undesirable for the patient to participate in the trial or which would jeopardise compliance with the protocol, or active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV). Screening for chronic conditions is not required.\n5. Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of osimertinib.\n6. Any of the following cardiac criteria:\n\n   * Mean resting corrected QT interval (QTc) \\> 470 msec obtained from 3 electrocardiograms (ECGs), using the screening clinic ECG machine derived QTc value. Whenever QTc, is mentioned in this document, this refers to correction e made by Fridericia formula (QTcF),\n   * Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG e.g. complete left bundle branch block, third degree heart block and second degree heart block.\n   * Patient with any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, electrolyte abnormalities (including: Serum\u002Fplasma potassium \\\u003C lower limit of normal (LLN); Serum\u002Fplasma magnesium \\\u003C LLN; Serum\u002Fplasma calcium \\\u003C LLN) , congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age in first degree relatives or any concomitant medication known to prolong the QT interval and cause Torsades de Pointes\n7. Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease.\n8. Inadequate bone marrow reserve or organ function (as demonstrated by any of the following laboratory values:\n\n   * Absolute neutrophil count \\\u003C1.5 x 109\u002FL;\n   * Platelet count \\\u003C100 x 109\u002FL;\n   * Haemoglobin \\\u003C90 g\u002FL;\n   * Alanine aminotransferase \\>2.5 times upper limit of normal (ULN) if no demonstrable liver metastases or \\>5 times ULN in the presence of liver metastases;\n   * Aspartate aminotransferase \\>2.5 times ULN if no demonstrable liver metastases or \\>5 times ULN in the presence of liver metastases;\n   * Total bilirubin \\>1.5 times ULN if no liver metastases or \\>3 times ULN in the presence of documented Gilbert's Syndrome \\[unconjugated hyperbilirubinaemia\\] or liver metastases;\n   * Serum creatinine \\>1.5 times ULN concurrent with creatinine clearance \\\u003C50 mL\u002Fmin \\[measured or calculated by Cockcroft and Gault equation\\]-confirmation of creatinine clearance is only required when creatinine is \\>1.5 times ULN.\n9. Women who are breast-feeding\n10. Males and females of reproductive potential who are not using and effective method of birth control and females who are pregnant or breastfeeding or have a positive (urine or serum) pregnancy test prior to study entry.\n11. Involvement in the planning and conduct of the study (applies to AstraZeneca staff or staff at the study site).\n12. History of hypersensitivity to active or inactive excipients of osimertinib or drugs with a similar chemical structure or class to osimertinib.",true,"30 Years",{"count":322,"type":22},59,[301],"This is an open label, phase II study to assess the efficacy of osimertinib (80 mg, orally, once daily) to suppress the progression of remaining GGN(s) in other lobes following surgical resection for actionable EGFR mutation-positive stage IB-IIIA lung adenocarcinoma.",[326],"Lung Adenocarcinoma",{"date":258,"type":39},{"date":329,"type":39},"2022-09-11",{"date":331,"type":22},"2027-12-01",{"name":44,"class":45},{"id":334,"slug":335,"hasResults":12,"nctId":336,"briefTitle":337,"officialTitle":338,"acronym":4,"eligibilityCriteria":339,"healthyVolunteers":12,"sex":18,"minAge":320,"maxAge":55,"enrollmentInfo":340,"targetDuration":4,"studyType":23,"phases":342,"briefSummary":343,"conditions":344,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":346,"startDateStruct":348,"completionDateStruct":349,"leadSponsor":350,"locationsCount":351},"100407866","phase-2-osimertinib-to-suppress-the-progression-of-ggnegfr-mutation-positive-100407866","NCT04591002","Osimertinib to Suppress the Progression of GGN(EGFR Mutation-positive)","A Phase II, Study of Osimertinib to Suppress the Progression of Remaining Ground-glass Opacity Nodule (GGN) in Other Lobes After Curative Resection for Actionable EGFR Mutation-positive Stage IB-IIIA Lung Adenocarcinoma","Inclusion Criteria:\n\n1. Provision of informed consent prior to any study specific procedures\n2. Adult male or female patients, aged from 30 to 75 years\n3. Pathologic proven stage I lung adenocarcinoma with additional persistent GGNs in at least one other lobe: GGN is defined as a ground glass-opacity with well-defined margin, mean density above -500 HU and greater than 7.5 mm in its maximum diameter\n4. The resected lung adenocarcinoma should have actionable EGFR mutation, which is limited to L858R or exon 19 deletion.\n5. WHO performance status 0-1 with no deterioration over the previous 2 weeks and a minimum life expectancy of 12 weeks\n6. Uneventful recovery from curative-intent lung cancer surgery\n7. Female subjects should be using highly effective contraceptive measures, and must have a negative pregnancy test and not be breast-feeding prior to start of dosing if of childbearing potential or must have evidence of non-child-bearing potential by fulfilling one of the following criteria at screening:\n\n   * Post-menopausal defined as aged more than 50 years and amenorrheic for at least 12 months following cessation of all exogenous hormonal treatments\n   * Women under 50 years old would be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and with LH and FSH levels in the post-menopausal range for the institution\n   * Documentation of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation Further information in Appendix E (Definition of Women of Childbearing Potential and Acceptable Contraceptive Methods)\n8. Male subjects should be willing to use barrier contraception (see Restrictions, Section 3.8)\n\nExclusion Criteria:\n\n1. Treatment with any neoadjuvant therapy (radiation, any cytotoxic chemotherapy, investigational agents or other anticancer drugs after surgery) before randomization\n2. Treatment with any adjuvant therapy (any cytotoxic chemotherapy, investigational agents or other anticancer drugs after surgery) before randomization\n3. Extensive surgery other than lobectomy or sublobar resection (i.e. bilobectomy, sleeve lobectomy, pneumonectomy)\n4. Past history of postoperative ALI\u002FARDS or pneumonia during recovery period\n5. Currently receiving (or unable to stop use prior to receiving the first dose of study treatment) medications or herbal supplements known to be strong inducers of CYP3A4 (at least 3 week prior) (Appendix C). All patients must try to avoid concomitant use of any medications, herbal supplements and\u002For ingestion of foodswith known inducer effects on CYP3A4.\n6. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses, which in the investigator's opinion makes it undesirable for the patient to participate in the trial or which would jeopardise compliance with the protocol, or active infection including hepatitis B, hepatitis and human immunodeficiency virus (HIV). Screening for chronic conditions is not required.\n7. Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of osimertinib.\n8. Any of the following cardiac criteria:\n\n   * Mean resting corrected QT interval (QTc) \\> 470 msec obtained from 3 electrocardiograms (ECGs), using the screening clinic ECG machine derived QTc value. Whenever QTc, is mentioned in this document, this refers to correction e made by Fridericia formula (QTcF),\n   * Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG e.g. complete left bundle branch block, third degree heart block and second degree heart block.\n   * Patient with any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, electrolyte abnormalities (including: Serum\u002Fplasma potassium \\\u003C LLN; Serum\u002Fplasma magnesium \\\u003C LLN; Serum\u002Fplasma calcium \\\u003C LLN) , congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age in first degree relatives or any concomitant medication known to prolong the QT interval and cause Torsades de Pointes\n9. Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease.\n10. Inadequate bone marrow reserve or organ function (as demonstrated by any of the following laboratory values:\n\n    * Absolute neutrophil count \\\u003C1.5 x 109\u002FL;\n    * Platelet count \\\u003C100 x 109\u002FL;\n    * Haemoglobin \\\u003C90 g\u002FL;\n    * Alanine aminotransferase \\>2.5 times ULN if no demonstrable liver metastases or \\>5 times ULN in the presence of liver metastases;\n    * Aspartate aminotransferase \\>2.5 times ULN if no demonstrable liver metastases or \\>5 times ULN in the presence of liver metastases;\n    * Total bilirubin \\>1.5 times ULN if no liver metastases or \\>3 times ULN in the presence of documented Gilbert's Syndrome \\[unconjugated hyperbilirubinaemia\\] or liver metastases;\n    * Serum creatinine \\>1.5 times ULN concurrent with creatinine clearance \\\u003C50 mL\u002Fmin \\[measured or calculated by Cockcroft and Gault equation\\]-confirmation of creatinine clearance is only required when creatinine is \\>1.5 times ULN.\n11. Women who are breast-feeding.\n12. Males and females of reproductive potential who are not using and effective method of birth control and females who are pregnant or breastfeeding or have a positive (urine or serum) pregnancy test prior to study entry.\n13. Involvement in the planning and conduct of the study (applies to AstraZeneca staff or staff at the study site).\n14. Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements.",{"count":341,"type":22},43,[301],"This study designed to assess the efficacy of osimertinib (80 mg, orally, once daily) to suppress the progression of remaining GGN(s) in other lobes following surgical resection for actionable EGFR mutation-positive stage I lung adenocarcinoma.",[345],"Lung Cancer",{"date":347,"type":39},"2026-04-30",{"date":329,"type":39},{"date":331,"type":22},{"name":44,"class":45},2,{"id":353,"slug":354,"hasResults":12,"nctId":355,"briefTitle":356,"officialTitle":357,"acronym":4,"eligibilityCriteria":358,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":359,"targetDuration":297,"studyType":125,"phases":4,"briefSummary":361,"conditions":362,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":365,"lastUpdatePostDateStruct":366,"startDateStruct":367,"completionDateStruct":369,"leadSponsor":371,"locationsCount":46},"100623190","identifying-risk-factors-and-predicting-future-health-outcomes-for-korean-patients-with-heart-and-blood-vessel-diseases-a-long-term-follow-up-study-100623190","NCT07393412","Identifying Risk Factors and Predicting Future Health Outcomes for Korean Patients With Heart and Blood Vessel Diseases: A Long-term Follow-up Study","PRIME (Precision Registry for Integrated Cardio-cerebrovascular Medicine & Evidence)","Inclusion Criteria:\n\nA patient who visited Samsung Medical Center due to cardiovascular and cerebrovascular disease.\n\nExclusion Criteria:\n\nA patient deemed unable to participate in the study based on the judgment of the medical staff.",{"count":360,"type":22},800000,"This study aims to establish a comprehensive, long-term clinical registry infrastructure for heart and brain vascular diseases (cardiovascular diseases and stroke) at Samsung Medical Center. In South Korea, these diseases are a leading cause of death, with a rapidly increasing burden due to an aging population and changing lifestyles. Despite this, there is a lack of large-scale, systematic data specifically focused on the long-term clinical course and unique characteristics of Korean patients.\n\nThe central hypothesis of this study is that the establishment of a standardized registry infrastructure-integrating both retrospective (historical) and prospective (future) data collection-will provide a more accurate and comprehensive understanding of the natural history and risk factors of heart and brain vascular diseases in the Korean population than currently available fragmented data. By combining existing medical records with ongoing patient follow-up, this infrastructure will serve as a critical scientific platform for developing personalized prevention and precision medicine strategies.\n\nBy building this organized data collection system, the study will:\n\nConstruct a robust infrastructure to collect uniform, high-quality clinical data, encompassing both past medical history (retrospective) and future clinical progress (prospective) from a large population of Korean patients.\n\nMonitor long-term health outcomes and the progression of diseases by tracking patients over many years.\n\nAnalyze the interaction between various risk factors and patient outcomes to identify population-specific patterns.\n\nCreate a scalable platform that can integrate advanced technologies, such as multi-omics and digital health tools, for future research.\n\nUltimately, this integrated registry infrastructure is expected to provide the essential scientific evidence needed to optimize clinical guidelines and improve the long-term quality of life for patients with heart and brain vascular diseases in Korea.",[363,364],"Cardiovascular Diseases (CVD)","Cerebro Vascular Disease","2026-04-23",{"date":258,"type":39},{"date":368,"type":39},"2026-02-02",{"date":370,"type":22},"2040-12-31",{"name":44,"class":45},{"id":373,"slug":374,"hasResults":12,"nctId":375,"briefTitle":376,"officialTitle":377,"acronym":378,"eligibilityCriteria":379,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":380,"enrollmentInfo":381,"targetDuration":4,"studyType":23,"phases":383,"briefSummary":384,"conditions":385,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":365,"lastUpdatePostDateStruct":388,"startDateStruct":390,"completionDateStruct":392,"leadSponsor":394,"locationsCount":46},"100580440","effect-of-untact-upper-extremity-rehabilitation-using-smart-glove-for-late-subacute-and-chronic-patients-with-brain-disorder-100580440","NCT06837324","Effect of Untact Upper Extremity Rehabilitation Using Smart Glove for Late Subacute and Chronic Patients With Brain Disorder","A Multicenter Confirmation Clinical Trial of Untact Upper Extremity Rehabilitation Using Smart Glove for Late Subacute and Chronic Patients With Brain Disorder - a Randomized Single-blinded Controlled Trial","brain disorder","Inclusion Criteria:\n\n* Patients with brain disorder aged 19 to 85 years old\n* patients with hemiparesis lasting for more than 3 months due to neurological diseases (stroke, traumatic brain injury, brain tumor) and impaired upper limb function\n* Patients with spasticity of the wrist and finger flexors and extensors on the affected side, with a Modified Ashworth Scale (MAS) score of 1+ or lower\n* Participants with sufficient cognitive function to understand the instructions from the researcher and the smart glove, and to perform the tasks (K-MMSE ≥21)\n\nExclusion Criteria:\n\n* pre-existing significant neurogenic disorders\n* major psychiatric disorders such as schizophrenia, bipolar disorder, or dementia\n* History of diseases that caused pain or muscle atrophy in the affected upper limb before the onset of the neurological disease, which interfered with rehabilitation\n* Severe spasticity of the affected upper limb (Modified Ashworth Scale score ≥3)\n* skin disorders or open wounds on the affected upper limb\n* Amputation, fractures, or soft tissue-related diseases or injuries on the affected upper limb\n* severe pain that interferes with rehabilitation of the affected upper limb (Numeric Rating Scale \\> 6)\n* Inability to maintain a seated posture for more than 10 minutes\n* Significant visual impairment to the extent that the screen cannot be recognized when using the smart glove","85 Years",{"count":382,"type":22},40,[58],"The aim is to clinically validate the clinical efficacy, usability, and safety of home-based upper limb rehabilitation training using the Neofect Smart Glove by comparing the effects between a group using the home-based Neofect Smart Glove and a group performing conventional home-based occupational therapy in patients with upper limb dysfunction in the late subacute and chronic stages of neurological diseases.",[386,387],"Brain Disorder","Home Based Rehabilitation",{"date":389,"type":39},"2026-04-24",{"date":391,"type":39},"2025-04-11",{"date":393,"type":22},"2026-12-31",{"name":44,"class":45},{"id":396,"slug":397,"hasResults":12,"nctId":398,"briefTitle":399,"officialTitle":400,"acronym":4,"eligibilityCriteria":401,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":380,"enrollmentInfo":402,"targetDuration":4,"studyType":23,"phases":403,"briefSummary":404,"conditions":405,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":365,"lastUpdatePostDateStruct":406,"startDateStruct":407,"completionDateStruct":409,"leadSponsor":410,"locationsCount":46},"100580443","effect-of-untact-upper-extremity-rehabilitation-using-a-smart-board-for-late-subacute-and-chronic-patients-with-brain-disorder-100580443","NCT06837363","Effect of Untact Upper Extremity Rehabilitation Using a Smart Board for Late Subacute and Chronic Patients With Brain Disorder","A Multicenter Confirmation Clinical Trial of Untact Upper Extremity Rehabilitation Using Smart Board for Late Subacute and Chronic Patients With Brain Disorder - a Randomized Single-blinded Controlled Trial","Inclusion Criteria:\n\n* Patients with neurological diseases aged 19 to 85 years old\n* Patients with hemiparesis lasting for more than 3 months due to neurological diseases (stroke, traumatic brain injury, brain tumor) and impaired upper limb function\n* Patients with shoulder flexor and adductor muscle strength of MRC grade 2 or higher\n* Patients with shoulder extensor and abductor spasticity of MAS grade 1+ or lower\n* Participants with sufficient cognitive function to understand the instructions from the researcher and the smart board, and to perform the tasks (K-MMSE ≥21)\n\nExclusion Criteria:\n\n* pre-existing significant neurogenic disorders\n* major psychiatric disorders such as schizophrenia, bipolar disorder, or dementia\n* History of diseases that caused pain or muscle atrophy in the affected upper limb before the onset of the neurological disease, which interfered with rehabilitation\n* Severe spasticity of the affected upper limb (Modified Ashworth Scale score ≥3)\n* skin disorders or open wounds on the affected upper limb\n* Amputation, fractures, or soft tissue-related diseases or injuries on the affected upper limb\n* severe pain that interferes with rehabilitation of the affected upper limb (Numeric Rating Scale \\> 6)\n* Inability to maintain a seated posture for more than 10 minutes, which is required for using the smart board\n* Significant visual impairment to the extent that the screen cannot be recognized when using the smart board",{"count":382,"type":22},[58],"The aim is to clinically validate the clinical efficacy, usability, and safety of home-based upper limb rehabilitation training using the Neofect Smart Board by comparing the effects between a group using the home-based Neofect Smart Board and a group performing conventional home-based occupational therapy in patients with upper limb dysfunction in the late subacute and chronic stages of neurological diseases.",[387,386],{"date":389,"type":39},{"date":408,"type":39},"2025-04-01",{"date":393,"type":22},{"name":44,"class":45},{"id":412,"slug":413,"hasResults":12,"nctId":414,"briefTitle":415,"officialTitle":416,"acronym":4,"eligibilityCriteria":417,"healthyVolunteers":12,"sex":18,"minAge":122,"maxAge":4,"enrollmentInfo":418,"targetDuration":4,"studyType":125,"phases":4,"briefSummary":420,"conditions":421,"keywords":423,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":365,"lastUpdatePostDateStruct":426,"startDateStruct":427,"completionDateStruct":429,"leadSponsor":431,"locationsCount":46},"100552925","a-clinical-study-for-developing-artificial-intelligenceai-based-clustering-model-for-personalized-medicine-in-acute-respiratory-failure-100552925","NCT06479421","A Clinical Study for Developing Artificial Intelligence(AI)-Based Clustering Model for Personalized Medicine in Acute Respiratory Failure","A Clinical Study for Developing AI-based Clustering Model for Personalized Medicine in Acute Respiratory Failure: Single Center, Prospective Cohort Study","\\# Inclusion Criteria:\n\n\\- Acute Respiratory Failure group\n\nAmong patients admitted to the internal medicine intensive care unit at Samsung Seoul Hospital, if all of the following conditions are met:\n\n1\\) Age 18 or older 2) Patients who require treatment with high flow nasal cannula (HFNC), non-invasive ventilation (NIV (BIPAP or CPAP)), or mechanical ventilation (MV) due to acute respiratory failure.\n\n\\- control group For comparative analysis, among patients admitted to the internal medicine intensive care unit at Samsung Seoul Hospital who meet all of the following conditions, they are registered as a control group with the consent of the subjects and undergo the same research procedure.\n\n1. Age 18 or older\n2. Patients who do not require high flow nasal cannula (HFNC), non-invasive ventilation (NIV (BIPAP or CPAP)), or mechanical ventilation (MV) treatment\n\n   * Exclusion Criteria:\n\nIf any of the following criteria applies, participants will not be permitted to participate in this clinical trial.\n\n1. Patients 48 hours after oxygen treatment (HFNC, NIV (BIPAP or CPAP), MV)\n2. Patients transferred from another hospital\n3. Patients with limitations in treatment",{"count":419,"type":22},250,"The investigators will prospectively collect clinical information to develop a clustering analysis model and confirm phenotype for patients with acute respiratory failure who admit to the intensive care unit and require oxygen supply beyond a high flow nasal cannula, and a control group without acute respiratory failure. and clinical characteristics and prognosis will be compared.",[422],"Acute Respiratory Failure",[424,425],"phenotyping","clustering analysis",{"date":258,"type":39},{"date":428,"type":39},"2023-08-14",{"date":430,"type":22},"2029-04-30",{"name":44,"class":45},{"id":433,"slug":434,"hasResults":12,"nctId":435,"briefTitle":436,"officialTitle":437,"acronym":4,"eligibilityCriteria":438,"healthyVolunteers":12,"sex":18,"minAge":439,"maxAge":4,"enrollmentInfo":440,"targetDuration":4,"studyType":23,"phases":442,"briefSummary":443,"conditions":444,"keywords":446,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":365,"lastUpdatePostDateStruct":450,"startDateStruct":451,"completionDateStruct":453,"leadSponsor":455,"locationsCount":46},"100543034","personalized-rtms-protocol-based-on-functional-reserve-to-enhance-ambulatory-function-in-pd-patients-100543034","NCT06350617","Personalized rTMS Protocol Based on Functional Reserve to Enhance Ambulatory Function in PD Patients","Safety and Efficacy of Personalized Repetitive Transcranial Magnetic Stimulation Protocol Based on Functional Reserve to Enhance Ambulatory Function in Patients With Parkinson Disease","Inclusion Criteria:\n\n1. patients with Parkinson's disease, diagnosed by the United Kingdom (UK) Parkinson's Disease Society Brain Bank Diagnostic Criteria,\n2. Modified Hoehn and Yahr (H\\&Y) scale, stage 2\\~4,\n3. patients who can walk on flat surfaces without the need for a gait aid,\n4. aged ≥50 years old,\n5. patients willing to sign the informed consent.\n\nExclusion Criteria:\n\n1. those with contraindications to rTMS, such as epilepsy, implanted metal objects in the head, or a history of craniotomy,\n2. those with cognitive impairment, confirmed through the Montreal Cognitive Assessment (MoCA) test as follows: \\\u003C 7 points: Illiterate \\\u003C 13 points: Education duration 0.5-3 years \\\u003C 16 points: Education duration 4-6 years \\\u003C 19 points: Education duration 7-9 years \\\u003C 20 points: Education duration 10 years or more\n3. those with coexisting neurological conditions, such as spinal cord injury or Stroke,\n4. those with major psychiatric disorders, such as major depression, schizophrenia, or dementia,\n5. those with severe on-off phenomena or severe dyskinesia, deemed by the investigators to render participation in the study inappropriate.\n6. those having contraindications to conduct an MRI study,\n7. those who are pregnant or lactating,\n8. patients who have refused to participate in this study.","50 Years",{"count":441,"type":22},60,[58],"The objective of this study was to determine the effects of protocols of repetitive transcranial magnetic stimulation (rTMS) therapy based on the functional reserve of each patient with Parkinson's disease, compared to conventional high-frequency rTMS therapy on bilateral primary motor cortex (M1). Investigators hypothesized that the functional reserve of each patient with Parkinson's disease will be different, and therefore an appropriate simulating target for rTMS therapy is needed. In addition, this approach could be more effective compared to conventional protocols applied to patient with Parkinson's disease regardless of their severity, predicted mechanism of motor function recovery, or functional reserves.",[445],"Parkinson's Disease and Parkinsonism",[447,448,449],"Parkinson's Disease","rTMS","Functional reserve",{"date":258,"type":39},{"date":452,"type":39},"2024-02-20",{"date":454,"type":22},"2026-09-30",{"name":44,"class":45},{"id":457,"slug":458,"hasResults":12,"nctId":459,"briefTitle":460,"officialTitle":461,"acronym":4,"eligibilityCriteria":462,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":463,"targetDuration":4,"studyType":23,"phases":465,"briefSummary":466,"conditions":467,"keywords":469,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":365,"lastUpdatePostDateStruct":470,"startDateStruct":471,"completionDateStruct":473,"leadSponsor":474,"locationsCount":46},"100536854","efficacy-of-personalized-repetitive-transcranial-magnetic-stimulation-protocol-based-on-functional-reserve-to-enhance-upper-limb-function-in-subacute-stroke-patients-100536854","NCT06270238","Efficacy of Personalized Repetitive Transcranial Magnetic Stimulation Protocol Based on Functional Reserve to Enhance Upper Limb Function in Subacute Stroke Patients","Efficacy of Personalized Repetitive Transcranial Magnetic Stimulation Protocol Based on Functional Reserve to Enhance Upper Limb Function in Subacute Stroke Patients: A Multi Center, Randomized, Single Blind, Parallel Group Prospective Clinical Trial","Inclusion Criteria:\n\n1. hemiplegic stroke patients in the subacute phase (7 days to 3 months from the onset) who are currently hospitalized,\n2. FMA score of the upper extremity ≤42,\n3. adequate language and cognitive function to perform at least a 1-step obey-command,\n4. pre-stroke functional level of modified Rankin Scale (mRS) ≤1,\n5. aged ≥19 years old,\n6. patients willing to sign the informed consent.\n\nExclusion Criteria:\n\n1. those with contraindications to rTMS, such as epilepsy, implanted metal objects in the head, or a history of craniotomy,\n2. those with progressive of hemodynamically unstable medical conditions,\n3. those with coexisting neurological conditions, such as spinal cord injury or Parkinson's disease,\n4. those with major psychiatric disorders, such as major depression, schizophrenia, or dementia,\n5. those having contraindications to conduct an MRI study,\n6. those who are pregnant or lactating ,\n7. patients who have refused to participate in this study.",{"count":464,"type":22},120,[58],"The objective of this study was to determine the effects of protocols of repetitive transcranial magnetic stimulation (rTMS) therapy based on the functional reserve of each hemiplegic stroke patient in subacute phase, compared to conventional low-frequency rTMS therapy on contralateral M1. Investigators hypothesized that the functional reserve of each hemiplegic stroke patient will be different, and therefore an appropriate simulating target for rTMS therapy is needed. In addition, this approach could be more effective compared to conventional protocols applied to stroke patients regardless of their severity, predicted mechanism of motor function recovery, or functional reserves.",[468],"Stroke",[468,448,449],{"date":389,"type":39},{"date":472,"type":39},"2024-02-13",{"date":454,"type":22},{"name":44,"class":45},{"id":476,"slug":477,"hasResults":12,"nctId":478,"briefTitle":479,"officialTitle":480,"acronym":4,"eligibilityCriteria":481,"healthyVolunteers":12,"sex":18,"minAge":122,"maxAge":482,"enrollmentInfo":483,"targetDuration":226,"studyType":125,"phases":4,"briefSummary":485,"conditions":486,"keywords":488,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":365,"lastUpdatePostDateStruct":490,"startDateStruct":491,"completionDateStruct":493,"leadSponsor":494,"locationsCount":46},"100294752","prospective-cohort-for-adult-hemophagocytosis-100294752","NCT03117010","Prospective Cohort for Adult Hemophagocytosis","A Prospective Cohort for Subjects With Adult Hemophagocytic Lymphohistiocytosis Like Syndrome","Inclusion Criteria:\n\n* Subjects should fulfill the following criteria\n\n  1. Subjects should have at least one of the following problems\n\n     1. Presence of hemophagocytosis in tissue or bone marrow\n     2. Presence of at least 3 conditions among 8 conditions of HLH diagnostic criteria\n  2. Age \\> 18 years\n  3. Written informed consents\n\n     Exclusion Criteria:\n* Subjects cannot satisfy the inclusion criteria","80 Years",{"count":484,"type":22},81,"This prospective study enrolls subjects who have clinical and laboratory manifestations related with hemophagocytic lymphohistiocytosis. The purpose of the study is to evaluate clinical and biological features of adult hemophagocytic lymphohistiocytosis. The enrolled subjects into this study will be evaluated according to the HLH (hemophagocytic lymphohistiocytosis)criteria and treated with systemic immunosuppressive therapy or chemotherapy. All subjects will be regularly monitored by physicians participating in this study.",[487],"Hemophagocytic Lymphohistiocytoses",[489],"Hemophagocytic lymphohistiocytosis",{"date":389,"type":39},{"date":492,"type":39},"2017-01-01",{"date":215,"type":22},{"name":44,"class":45},{"id":496,"slug":497,"hasResults":12,"nctId":498,"briefTitle":499,"officialTitle":499,"acronym":4,"eligibilityCriteria":500,"healthyVolunteers":12,"sex":18,"minAge":297,"maxAge":4,"enrollmentInfo":501,"targetDuration":4,"studyType":125,"phases":4,"briefSummary":503,"conditions":504,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":365,"lastUpdatePostDateStruct":507,"startDateStruct":508,"completionDateStruct":510,"leadSponsor":511,"locationsCount":512},"100261924","the-molecular-screening-study-for-the-umbrella-trial-sukses-in-relapsed-small-cell-lung-cancer-patients-sukses-s-100261924","NCT02688894","The Molecular Screening Study for the Umbrella Trial (SUKSES) in Relapsed Small Cell Lung Cancer Patients [SUKSES-S]","Inclusion Criteria:\n\n1. Provision of fully informed consent prior to any study specific procedures.\n2. Patients must be ≥20 years of age.\n3. Histologically or cytologically confirmed Small cell lung cancers\n4. ECOG performance status of 0 to 2\n5. Patients who are being treated or were treated with platinum-based chemotherapy as a first-line treatment\n6. Patients with available archival tissues for molecular analysis or patients who agreed with biopsy for molecular analysis\n\nExclusion Criteria:\n\n1. More than two prior chemotherapy regimen for the treatment of small cell lung cancer\n2. Pregnant or nursing women (women of reproductive potential have to agree to use an effective contraceptive method)\n3. Patients with second primary cancer, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours curatively treated with no evidence of disease for ≤2 years.",{"count":502,"type":22},797,"This protocol is a molecular screening protocol only. No drug intervention study will be included in this protocol. Based on the molecular profiling, patients may be eligible for drug intervention study of SUKSES trial.\n\nThis procedure can be performed during or after the first-line treatment. DNA will be extracted from the archived or fresh tissue and blood. NGS-based cancer panel and Nanostring CNV will be tested with DNA from tissue and\u002For blood.\n\nImmunohistochemistry and FISH will be done by pathologists using archived or fresh tissue.\n\nTumor tissues (fresh or archival) will be analyzed using NGS-based cancer panel, nanostring CNV, immunohistochemistry and\u002For FISH.\n\nSpecific methods of each molecular tests will be defined with standard laboratory manual developed by pathologists.",[505,506],"Small Cell Lung Cancers","Neuroendocrine Carcinoma",{"date":258,"type":39},{"date":509,"type":39},"2016-04-29",{"date":238,"type":22},{"name":44,"class":45},6,{"id":514,"slug":515,"hasResults":12,"nctId":516,"briefTitle":517,"officialTitle":518,"acronym":519,"eligibilityCriteria":520,"healthyVolunteers":12,"sex":18,"minAge":122,"maxAge":4,"enrollmentInfo":521,"targetDuration":4,"studyType":23,"phases":523,"briefSummary":525,"conditions":526,"keywords":530,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":535,"lastUpdatePostDateStruct":536,"startDateStruct":537,"completionDateStruct":539,"leadSponsor":541,"locationsCount":351},"100558549","phase-1-selinexor-with-ice-chemotherapy-in-secondary-central-nervous-system-involving-b-cell-non-hodgkin-lymphoma-100558549","NCT06552559","Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma","Phase 1\u002F2 Study of Selinexor With Dexamethasone, Ifosfamide, Carboplatin, and Etoposide in Patients Who Have Secondary Central Nervous System Involvement With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma","SIENA","Inclusion Criteria:\n\n* Patients must have histologically confirmed B-cell NHL with CNS involvement DLBCL including ABC, GCB or PMBCL subtypes Indolent lymphomas transformed to aggressive lymphomas Follicular lymphomas\n* Patients must have received at least one cycles of anthracycline based chemotherapy administered with curative intent\n* Patients must be age ≥18 years.\n* Patients must have at least one site of measurable disease, 1.5 cm in diameter or greater.\n* Patients must have ECOG performance status of 0-2.\n* Patients must have laboratory test results within these ranges: Absolute neutrophil count ≥ 1500\u002Fmm³, Platelet count ≥ 100,000\u002Fmm³, Serum creatinine clearance ≥40 mL\u002Fmin, Total bilirubin ≤ 1.5x ULN (Higher levels are acceptable if these can be attributed to active hemolysis or ineffective erythropoiesis.), AST (SGOT) and ALT (SGPT) ≤ 2x ULN\n* Women of childbearing potential must agree to use dual methods of contraception and have a negative serum pregnancy test prior to selinexor treatment. Male patients must use an effective barrier method of contraception if sexually active with a female of child-bearing potential.\n* Patients must be able to understand and willing to sign a written informed consent document.\n* Patients must be able to adhere to the study visit schedule and other protocol requirements.\n* Patients must not have any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.\n* Patients must not have any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he\u002Fshe were to participate in the study or confounds the ability to interpret data from the study.\n* Patients with hepatitis B virus including HBsAg-positive carrier or IgG anti- HBc-positive can be enrolled if they can receive anti-viral prophylaxis\n\nExclusion Criteria:\n\n* Patients cannot fulfill the above-mentioned inclusion criteria\n* Patients with primary CNS lymphoma\n* Patients with a prior history with selinexor",{"count":522,"type":22},37,[524,301],"PHASE1","Secondary involvement of the central nervous system (CNS), such as CNS relapse after treatment or progression during treatment, is a rare but deadly occurrence in patients with B-cell non-Hodgkin lymphoma (NHL), particularly in cases of diffuse large B-cell lymphoma (DLBCL) and transformed follicular lymphoma (FL). Despite the grim prognosis associated with secondary CNS involvement, no definitive treatment strategy exists. Selinexor®, an oral, first-in-class, potent selective inhibitor of nuclear export that binds to XPO1, leads to the nuclear retention of tumor suppressor and growth regulator proteins, as well as topoisomerase II enzymes, thereby restoring their functions. Preclinical studies have also shown that selinexor can sensitize cancer cells to topoisomerase inhibitors, alkylating agents, and steroids. Selinexor has been approved by the Food and Drug Administration for relapsed or refractory DLBCL. We hypothesize that selinexor could work synergistically with ifosfamide (an alkylating agent) and etoposide (a topoisomerase II inhibitor) in the ifosfamide, carboplatin, and etoposide (ICE) regimen. High-dose dexamethasone was added to this regimen to enhance the efficacy of ICE as a salvage regimen for secondary CNS involvement, due to its ability to cross the blood-brain barrier.\n\nThis phase I\u002FII study aims to evaluate the efficacy and safety of selinexor in combination with ifosfamide, carboplatin, etoposide (ICE), and dexamethasone in patients with relapsed or refractory B-cell non-Hodgkin lymphoma with secondary CNS involvement.",[527,528,529],"B-cell Lymphoma Recurrent","B-cell Lymphoma Refractory","CNS Metastases",[531,532,533,534],"Non-Hodgkin B-cell lymphoma","Secondary CNS involvement","Selinexor","ICE","2026-04-22",{"date":365,"type":39},{"date":538,"type":39},"2024-05-01",{"date":540,"type":22},"2028-12-30",{"name":44,"class":45},{"id":543,"slug":544,"hasResults":12,"nctId":545,"briefTitle":546,"officialTitle":547,"acronym":548,"eligibilityCriteria":549,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":550,"targetDuration":4,"studyType":23,"phases":552,"briefSummary":553,"conditions":554,"keywords":558,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":562,"lastUpdatePostDateStruct":563,"startDateStruct":564,"completionDateStruct":566,"leadSponsor":567,"locationsCount":568},"100618290","artificial-intelligence-driven-medipixel-fractional-flow-reserve-versus-invasive-fractional-flow-reserve-guided-pci-trial-aim-ffr-trial-100618290","NCT07329699","Artificial Intelligence-Driven Medipixel Fractional Flow Reserve Versus Invasive Fractional Flow Reserve-Guided PCI Trial (AIM-FFR Trial)","Artificial Intelligence-Driven Angiography-Based Fractional Flow Reserve Versus Invasive Fractional Flow Reserve-Guided PCI","AIM-FFR","Inclusion Criteria:\n\n1. Subject must be at least 19 years of age\n2. Eligible for coronary angiography and\u002For percutaneous coronary intervention.\n3. Chronic coronary syndrome or acute coronary syndrome (non-culprit vessels only)\n4. Coronary artery disease in one or more native major epicardial vessels or their branches with reference vessel diameter of at least 2.5mm and with visually assessed coronary stenosis in which the physiological severity of the lesion is questionable (typically 40-90% diameter stenosis).\n5. Subject who is able to understand risks, benefits and treatment alternatives and sign informed consent voluntarily.\n\nExclusion Criteria:\n\n1. Patients unable to provide informed consent\n2. Patients with known intolerance to aspirin, P2Y12 inhibitors, or components of drug-eluting stents and drug-coated balloons\n3. Patients with coronary artery bypass grafting\n4. Patients who have non-cardiac co-morbid conditions with life expectancy \\\u003C1 year\n5. Patients with cardiogenic shock or cardiac arrest\n6. Patients with severe left ventricular systolic dysfunction (ejection fraction \\\u003C30%)\n7. Patients with severe valvular heart disease requiring open heart surgery\n8. Pregnant or lactating women\n9. Angiographic exclusion criteria\n\n   * Culprit vessel of patients with ST-elevation myocardial infarction (target lesions in non-culprit vessel can be enrolled)\n   * Chronic total occlusion (target lesions in vessels without chronic total occlusion can be enrolled)\n   * Ostial stenosis in left man coronary artery or right coronary artery\n   * Severe tortuosity of any target vessel\n   * Severe overlap in the stenosed segment\n   * Poor image quality precluding identification of vessel contours",{"count":551,"type":22},2100,[58],"The AIM-FFR trial is a prospective, multi-center, open-label, randomized controlled, non-inferiority trial. The current trial will evaluate non-inferiority of MPFFR-guided PCI, compared with invasive FFR-guided PCI in patients with coronary artery disease.",[555,556,557],"Coronary Artery Disease","Chronic Coronary Syndrome","Acute Coronary Syndrome",[559,560,561],"Coronary artery stenosis","Fractional flow reserve","Prognosis","2026-04-21",{"date":365,"type":39},{"date":565,"type":39},"2026-03-18",{"date":263,"type":22},{"name":44,"class":45},23,{"id":570,"slug":571,"hasResults":12,"nctId":572,"briefTitle":573,"officialTitle":574,"acronym":575,"eligibilityCriteria":576,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":577,"targetDuration":4,"studyType":23,"phases":579,"briefSummary":581,"conditions":582,"keywords":586,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":596,"lastUpdatePostDateStruct":597,"startDateStruct":599,"completionDateStruct":601,"leadSponsor":602,"locationsCount":46},"100541451","phase-4-anesthesia-and-non-small-cell-lung-cancer-recurrence-100541451","NCT06330038","Anesthesia and Non-small Cell Lung Cancer Recurrence","Recurrence Free Survival After Curative Resection of Non-small Cell Lung Cancer Between Inhalational Gas Anesthesia and Propofol-based Total IntraVenous Anesthesia: a Multicenter, Randomized, Clinical Trial","GASTIVA","Inclusion Criteria:\n\n* American Society of Anesthesiologists physical status (ASA) Ⅰ-Ⅲ\n* The Eastern Cooperative Oncology Group (ECOG) performance status 0-2\n* Lung resection surgery (segmentectomy, lobectomy, bilobectomy, pneumonectomy; video-assisted, robot-assisted, or open) with curative intent for NSCLC (clinical Tumor, Node, Metastasis (TNM) stage Ⅰ- ⅢA).\n\nExclusion Criteria:\n\n* Distant metastasis or malignant tumor in other organs that according to the attending surgeon is not in long-term remission\n* Severe neurologic conditions\n* Severe hepatic disease (Child-Pugh classification C)\n* Renal failure requiring renal replacement therapy\n* History of anesthesia and\u002For surgery within 1 yr\n* Previous surgery due to lung cancer (except diagnostic biopsies)\n* Contraindications to any study medication (history of allergy, hypersensitivity reaction, or any other contraindication)\n* Planned joint extrapulmonary procedure\n* Surgery under cardiopulmonary bypass or extracorporeal membrane oxygenation\n* Postoperative sedation\n* Pregnancy, or lactation\n* Patient refusal.",{"count":578,"type":22},5384,[580],"PHASE4","There has been ongoing debate about the relationship between cancer recurrence and anesthetic management. Therefore, the investigators will test the hypothesis that the recurrence free survival (RFS) after curative resection of NSCLC is higher in patient who received total intravenous anesthesia (TIVA) than volatile anesthetics in this multi-center randomized trials.",[583,584,585],"Non-small Cell Lung Cancer","Surgery","Anesthesia",[585,587,588,589,590,591,592,593,594,584,595],"Desflurane","Inhalational anesthesia","Isoflurane","Lung neoplasm","Metastasis","Propofol","Recurrence","Sevoflurane","Non-small cell lung cancer","2026-04-15",{"date":598,"type":39},"2026-04-20",{"date":600,"type":39},"2024-08-05",{"date":215,"type":22},{"name":44,"class":45},""]